Immunoadsorption of LPS, C5a and IL-6 in Severe Sepsis and Septic Shock (ISASS-1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine whether immunoadsorption of LPS, Il-6 and C5a reduces systemic hyperinflammation, improves immune function and improves organ function in patients with severe sepsis and septic shock
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Diagnosis of severe sepsis or septic shock (ACCP/SCCM)
Presence of 4 SIRS criteria/indicators
Suspected or proven infection (refer also to: 1.)
APACHE II score > 18
At least one acute organ dysfunction (renal/pulmonary/hemodynamics/cerebral)
Suspected or proven pregnancy
Absolute contraindication for anticoagulation (active bleeding)
History of anaphylactic reaction to egg-albumin
Participants in other clinical trials (<12 wks. prior to study inclusion)